Cited by 568Vagus Nerve Stimulation ResearchTreatment of Major DepressionNeurological disorders and treatments

Vagus nerve stimulation (VNS™) for treatment-resistant depression: efficacy, side effects, and predictors of outcome

Sackeim, H·2001·Neuropsychopharmacology

Abstract

This open pilot study of vagus nerve stimulation (VNS) in 60 patients with treatment-resistant major depressive episodes (MDEs) aimed to: 1) define the response rate; 2) determine the profile of side effects; and, most importantly; 3) establish predictors of clinical outcome. Participants were outpatients with nonatypical, nonpsychotic, major depressive or bipolar disorder who had not responded to at least two medication trials from different antidepressant classes in the current MDE. While on stable medication regimens, the patients completed a baseline period followed by device implantation. A 2-week, single blind, recovery period (no stimulation) was followed by 10 weeks of VNS. Of 59 completers (one patient improved during the recovery period), the response rate was 30.5% for the primary HRSD(28) measure, 34.0% for the Montgomery-Asberg Depression Rating Scale (MADRAS), and 37.3% for the Clinical Global Impression-Improvement Score (CGI-I of 1 or 2). The most common side effect was voice alteration or hoarseness, 55.0% (33/60), which was generally mild and related to output current intensity. History of treatment resistance was predictive of VNS outcome. Patients who had never received ECT (lifetime) were 3.9 times more likely to respond. Of the 13 patients who had not responded to more than seven adequate antidepressant trials in the current MDE, none responded, compared to 39.1% of the remaining 46 patients (p =.0057). Thus, VNS appears to be most effective in patients with low to moderate, but not extreme, antidepressant resistance. Evidence concerning VNS' long-term therapeutic benefits and tolerability will be critical in determining its role in treatment-resistant depression.

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(01)00271-8

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A pilot study that examined the application of VNS in 60 patients with treatment-resistant depressive disorder showed a significant clinical improvement in 30-37% of patients and a high tolerability.

    “A pilot study that examined the application of VNS in 60 patients with treatment-resistant depressive disorder showed a significant clinical improvement in 30–37% of patients and a high tolerability (78).”
  • Neurostimulation such as vagus nerve stimulation, deep brain stimulation, or electroconvulsive therapy carries a risk of infections and other potential side effects due to surgical implantation.

    “Neurostimulation, such as vagus nerve stimulation (VNS), deep brain stimulation (DBS), or electroconvulsive therapy (ECT), has been recommended and is effective for treatment-resistant depression; however, these interventions also possess a certain risk of developing infections and other potential side effects due to surgical implantation.[6–8]”
  • Neurostimulation such as vagus nerve stimulation, deep brain stimulation, or electroconvulsive therapy has been recommended and is effective for treatment-resistant depression.

    “Neurostimulation, such as vagus nerve stimulation (VNS), deep brain stimulation (DBS), or electroconvulsive therapy (ECT), has been recommended and is effective for treatment-resistant depression; however, these interventions also possess a certain risk of developing infections and other potential side effects due to surgical implantation.[6–8]”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sackeim, H.
Venue
Neuropsychopharmacology
Published
2001-11
Volume
25
Issue
5
Pages
713-728
ISSN
0893-133X (ISSN-L)
OpenAlex
W2171565404
Cited by
568
References
46
Citations by year
2026: 9 · 2025: 14 · 2024: 30 · 2023: 14 · 2022: 29 · 2021: 19 · 2020: 22 · 2019: 22 · 2018: 21 · 2017: 22 · 2016: 18 · 2015: 22 · 2014: 15 · 2013: 21 · 2012: 16
FWCI
14.22
Type
journal article
Language
en
Open access
closed
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • World Health Organization
  • Medical University of South Carolina
Topics
  • Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Keywords
vagus nerve stimulation, treatment-resistant depression, major depressive episode, bipolar disorder, predictors of treatment response, antidepressant resistance, adverse effects, voice change, device implantation, response rate
MeSH terms
Adolescent, Adult, Aged, Bipolar Disorder, Depressive Disorder, Drug Resistance, Electroconvulsive Therapy, Electrodes, Implanted, Electric Stimulation Therapy, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Quality of Life, Vagus Nerve, Treatment Outcome, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review